Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II trial of 2X-121 in recurrent ovarian cancer

Trial Profile

A Phase II trial of 2X-121 in recurrent ovarian cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs 2X 121 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2018 According to a Medical Prognosis Institute media release, this trial is expected to commence in Q1 2019.
    • 27 Aug 2018 According to a Medical Prognosis Institute media release, the Oncology Venture along with the Medical Prognosis Institute has received an Investigational Device Exemption (IDE) and its Investigational New Drug Application (IND) approval from the US FDA to initiate this study in USA and Germany.
    • 03 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top